Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SunWay Biotech CoROCO:1271 -4.39%90 EBITDA Margin % is 19.56% as of Dec. 2025, which is 18% below its 10-year median of 23.83. GuruFocus rates ROCO:1271 with a GF Score™ of 90/100 and a GF Value™ of NT$71.11 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,955 Consumer Packaged Goods companies, SunWay Biotech Co ranks better than 82.92% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SunWay Biotech Co's EBITDA for the
six
months ended in Dec. 2025 was NT$103.4 Mil. SunWay Biotech Co's Revenue for the
six
months ended in Dec. 2025 was NT$528.9 Mil. Therefore, SunWay Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 19.56%.
SunWay Biotech Co (ROCO:1271) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SunWay Biotech Co EBITDA Margin % Related Terms
SunWay Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SunWay Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, SunWay Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SunWay Biotech Co EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, SunWay Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SunWay Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SunWay Biotech Co (ROCO:1271) has a EBITDA Margin % of 19.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SunWay Biotech Co and its competitors. This is 18% below median its historical median of 23.83. Over the past decade, SunWay Biotech Co's EBITDA Margin % has ranged from 11.41 to 49.95. According to the industry distribution chart, SunWay Biotech Co ranks #334 out of 1955 companies in the Consumer Packaged Goods industry, placing it in the top 17.1%.
Is SunWay Biotech Co's EBITDA Margin % too high?
SunWay Biotech Co's current EBITDA Margin % of 19.56% is 18% below median its 10-year median of 23.83. Over the past 10 years, this metric has ranged from a low of 11.41 to a high of 49.95. The Consumer Packaged Goods industry median EBITDA Margin % is 9.01. SunWay Biotech Co's value of 19.56% is 117.1% above this industry median. Based on the distribution chart, SunWay Biotech Co ranks #334 out of 1955 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, SunWay Biotech Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SunWay Biotech Co's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, SunWay Biotech Co ranks #334 out of 1955 companies for EBITDA Margin %. This places SunWay Biotech Co in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.01. SunWay Biotech Co's value of 19.56% is 117.1% above this benchmark. Historically, SunWay Biotech Co's own EBITDA Margin % has ranged from 11.41 to 49.95 over the past decade. While the company's 10-year median is 23.83 vs. the industry median of 9.01, SunWay Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 9.01, based on 1,955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SunWay Biotech Co's current EBITDA Margin % of 19.56% is 117.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SunWay Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 9.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SunWay Biotech Co's current EBITDA Margin % is 19.56%, which is 18% below median its own 10-year median of 23.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SunWay Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, SunWay Biotech Co (ROCO:1271) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.11, compared to a current price of NT$61.00 — trading 14.2% below its estimated fair value. The current EBITDA Margin % is 19.56%, which is 18% below median its 10-year median of 23.83 and 117.1% above the Consumer Packaged Goods industry median of 9.01. SunWay Biotech Co's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SunWay Biotech Co (ROCO:1271), the current EBITDA Margin % is 19.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SunWay Biotech Co (ROCO:1271) Overvalued in 2026?
Based on GuruFocus' analysis, SunWay Biotech Co stock appears to be undervalued.
The current stock price of NT$61.00 is trading 14.2% below its estimated GF Value™ of NT$71.11.
GuruFocus considers SunWay Biotech Co to be Modestly Undervalued.
Key valuation signals for ROCO:1271:
EBITDA Margin %: 19.56% (18% below median its 10-year median of 23.83)
GF Value™: NT$71.11 vs. price of NT$61.00 (14.2% below fair value)
Industry Position: 117.1% above the Consumer Packaged Goods median (#334 of 1955)
No single metric tells the full story. See the ROCO:1271 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SunWay Biotech Co Ltd is engaged in the research, design and manufacturing of Monascus purpureus NTU 568, Lactobacillus paracasei subsp, paracasei NTU 101, and the related products.
90GF Score
Get the complete analysis for ROCO:1271
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1271 has been successfully added to your 
